TinyGemsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Third Fast Track Designation Validates REQORSA(R)’s Potential
Genprex (NASDAQ: GNPX), a gene therapy company, recently received U.S. FDA Fast Track Designation (“FTD”) for its lead product candidate, REQORSA(R) immunogene therapy, in combination with Tecentriq(R), a cancer immunotherapy treatment developed and sold by Genentech, Inc., in patients with extensive-stage small cell lung cancer (“ES-SCLC”) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. “The FTD is for the company’s Acclaim-3 patient population, and Genprex expects to initiate its Acclaim-3 clinical trial by enrolling the first patient in the third quarter of 2023… The company previously received two other FTDs. In 2020, Genprex…